explore -WSS

explore

author：entertainment 2025-08-24 10:14:52 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： 2023 STAT Wunderkinds: get to know the winners

WSS

Senate panel puts off hardest PBM reforms for another day

The EU Joint Clinical Assessment needs to live up to its promise

'Investigate these claims': UFO transparency at center of House hearing

NIH confirmation hearing shows politicization of research

NIH confirmation hearing shows politicization of research

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Wikipedia

explore

hotspot

Affirmative action in medical school literally saved lives

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

DIEP, the 'gold standard' of breast reconstruction, is under threat

Dems pitch expanding Medicare power to negotiate drug prices

Heart attack and stroke risk calculators need revising

First Opinion Podcast: Long Covid needs a new approach

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Studies point to risks of excluding people with obesity from drug trials

In Memoriam: Notable people who died in 2023

Why health workers in Gaza are injured or die at high rates

hotspot

Will the FTC rein in IQVIA's health data empire?

Biogen says it will cut costs by $700 million, slash 1,000 jobs

UHS says company favors patients whose insurance pays more

Why patients can’t get everything they want on drug pricing

Will Ozempic

What it's like to live with paralysis for one psychologist

explore

knowledge

explore

focus